Back

Residual thrombotic risk: from monotherapy to dual pathway inhibition.

29 August 2022 (14:30 - 14:45)
Organised by:
Congress Presentation Part of: How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Bianca Rocca

LUM University, Casamassima (Italy)

4 More presentations in this session

Presentation thumbnail
Residual risk in dyslipidaemias: from statins to PCSK9 inhibitors and beyond.
Professor E. Stroes (Amsterdam, NL)
Slides Video
Presentation thumbnail
Residual inflammatory risk.
Professor W. Koenig (Munich, DE)
Slides Video
Presentation thumbnail
Residual diabetic risk: from glucose lowering to cardiovascular protection.
Professor N. Marx (Aachen, DE)
Slides Video
Presentation thumbnail
How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options – discussion.
Video

Access the full session

Session thumbnail
How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options
Video

The Event

Event poster

ESC Congress 2022

29 August 2022 14:30 CET
You may be interested in
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
thumbnail
ESC TV Today
Episode 7: Coronary spasm - Sex differences in heart failure
thumbnail
Congress Session
Challenges in hypertension management

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources